Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: xiliotx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/21/2022 | $7.00 | Buy | Chardan Capital Markets |
| 1/10/2022 | $36.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $40.00 | Buy | Guggenheim |
| 11/16/2021 | $31.00 | Outperform | Raymond James |
| 11/16/2021 | Outperform | Cowen & Co. | |
| 11/16/2021 | $32.00 | Overweight | Morgan Stanley |
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am ESTNORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's p
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective February 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 83,400 shares of its common stock to four new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.705 per share, which is equal to the closing price of the company's common stock on January 31, 2025. Each stock option has a ten-year term and will vest as to 25% of the share
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) and improvement in clinical symptoms Data continue to demonstrate differentiated safety and tolerability profile for the combination with low incidence of immune-related adverse events Xilio Therapeutics to host investor conference call and webcast on Wednesday, January 22, 2025, at 8:30 am ET WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company
WALTHAM, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective January 1, 2025, the company granted a non-qualified stock option to purchase 60,000 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock option has an exercise price of $0.955 per share, which is equal to the closing price of the company's common stock on December 31, 2024. The stock option has a ten-year term and will vest as to 25% of the shares underlying the s
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective January 1, 2025, the company granted a non-qualified stock option to purchase 375,000 shares of its common stock to Caroline Hensley, its newly hired Chief Legal Officer, under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock option has an exercise price of $0.955 per share, which is equal to the closing price of the company's common stock on December 31, 2024. The stock option has a ten-year term and will vest as
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities Completed additional private placement with Gilead for purchase of remaining equity investment in connection with XTX301 partnership WALTHAM, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present initial data from its ongoing Phase 2 trial for vilastobart (XTX101), a tumor-activated, Fc-enhanced, high affi
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. "Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization," said René Russo, Pharm.D., president and chief executive officer of Xilio. "Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to ha
WALTHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective December 1, 2024, the company granted non-qualified stock options to purchase 8,400 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $1.09 per share, which is equal to the closing price of the company's common stock on November 29, 2024. Each stock option will have a ten-year term and will vest as to 25% of the shares underlying
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SCHEDULE 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
10-Q - Xilio Therapeutics, Inc. (0001840233) (Filer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
10-Q - Xilio Therapeutics, Inc. (0001840233) (Filer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am ESTNORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's p
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) and improvement in clinical symptoms Data continue to demonstrate differentiated safety and tolerability profile for the combination with low incidence of immune-related adverse events Xilio Therapeutics to host investor conference call and webcast on Wednesday, January 22, 2025, at 8:30 am ET WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company
Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically "cold" tumors Complete resolution of a metastatic liver lesion observed in a patient with microsatellite stable colorectal cancer (MSS CRC) Safety data indicated combination of vilastobart and atezolizumab was generally well-tolerated and support the potential of vilastobart to be a differentiated next-generation anti-CTLA-4 in combination with PD-(L)1 inhibitors Continue to anticipate initial data from Phase 2 trial for combination of vilastobart and atezolizumab in metastatic
Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at doses up to 4 mg/kg administered once every three weeks in outpatient setting, with no reported signs or symptoms of vascular leak syndrome Two patients continuing treatment for more than 1 year, demonstrating XTX202 was well-tolerated with repeated, long-term dosing Plan to evaluate XTX202 as a monotherapy in ongoing Phase 2 proof-of-concept trial at 4.0 mg/kg in patients with advanced melanoma and renal cell carci
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The call will feature
Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $36.00
Guggenheim initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $40.00
Raymond James initiated coverage of Xilio Therapeutics with a rating of Outperform and set a new price target of $31.00
Cowen & Co. initiated coverage of Xilio Therapeutics with a rating of Outperform
Morgan Stanley initiated coverage of Xilio Therapeutics with a rating of Overweight and set a new price target of $32.00
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. "Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization," said René Russo, Pharm.D., president and chief executive officer of Xilio. "Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to ha
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors. "On behalf of the entire board of directors, it is a privilege to welcome Aoife and James, both well-recognized biotech industry veterans, to the board of directors," said Paul Clancy, chair of the board of directors of Xilio Therapeutics. "Their extensive experience spanning all stages of drug development will be invaluable as Xilio progresses its
XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome XTX301, a tumor-activated IL-12, received FDA clearance for IND application; anticipate initiating patient dosing in Phase 1 clinical trial in first quarter of 2023 Plan to focus resources on advancing clinical-stage cytokine programs and will seek to partner XTX101, a tumor-activated anti-CTLA-4, to advance beyond ongoing Phase 1 monotherapy cohorts $139.1 million in cash and cash equivalents as of September 30, 2022, with anticipate
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the company's board of directors. Mr. Heyman is a biopharmaceutical veteran with nearly 40 years of leadership and management expertise in corporate strategy, business development and venture capital from his tenure with Johnson & Johnson (J&J). In addition, the company announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, will serve as a strategic advisor to Xilio's board of directors and its executive team.
XTX101, tumor-selective anti-CTLA-4, has successfully reached dose levels exceeding the target dose with limited active (unmasked) molecule in the periphery in ongoing Phase 1 clinical trial XTX202, tumor-selective IL-2, advancing in dose-escalation of Phase 1 clinical trial Investigational new drug application planned for XTX301, tumor selective IL-12, in fourth quarter of 2022 Uli Bialucha, Ph.D., promoted to Chief Scientific Officer and Chris Frankenfield promoted to Chief Legal and Administrative Officer Strong financial position with $159.4 million in cash and cash equivalents as of June 30, 2022 expected to provide cash runway into first half of 2024; multiple data mileston
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Stacey Davis has been appointed as chief business officer to further the company's corporate and business development strategy that will be central to its next stage of growth. "As an accomplished life science leader, Stacey brings significant strategic business experience building successful portfolios in oncology and immunology with an in-depth knowledge of the real-world patient and physician experience," said René Russo, Pharm.D., president and chief executive officer of